Nightstar Therapeutics plc (NITE) Tops Q3 EPS by 13c

Nightstar Therapeutics plc (NASDAQ: NITE) reported Q3 EPS of ($0.27), $0.13 better than the analyst estimate of ($0.40).

“We are pleased with the upcoming initiation of the Phase 2/3 expansion study in line with our previous guidance after being the first sponsor to establish proof-of-concept in X-linked retinitis pigmentosa,” said Dave Fellows, Chief Executive Officer. “The modified Phase 2/3 expansion study is designed to be consistent with recommendations in FDA’s draft guidance on the development of gene therapy products for retinal disorders, which we believe will allow us to expedite the development of NSR-RPGR.”

For earnings history and earnings-related data on Nightstar Therapeutics plc (NITE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Reading (RDI) Tops Q2 EPS by 4c
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c